Medtide Inc.

Medtide Inc. (Stock Code: 03380.HK) is a peptide-focused contract research, development, and manufacturing organization (CRDMO), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production. The company is headquartered in Hangzhou, China, and has commercial production bases and offices in both China and the United States. We have been deeply involved in the peptide field for over 20 years. Today, we have become a CRDMO with global operations and comprehensive service capabilities.

Medtide Inc. provides (i) contract research organization (CRO) services,namely peptide new chemical entity (NCE) discovery synthesis; and (ii) contract development and manufacturing organization (CDMO) services,namely peptide chemistry, manufacturing and controls (CMC) development and commercial manufacturing.